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http://www.biomedcentral.com/1471-230X/12/93RESEARCH ARTICLE Open AccessA magic pill? A qualitative analysis of patients’
views on the role of antidepressant therapy in
inflammatory bowel disease (IBD)
Antonina A Mikocka-Walus1,2*, Andrea L Gordon1, Benjamin J Stewart1,2 and Jane M Andrews3,4Abstract
Background: Studies with healthy volunteers have demonstrated that antidepressants can improve
immunoregulatory activity and thus they may have a potential to positively impact the disease course in
inflammatory bowel disease (IBD), a chronic and incurable condition. However, patients’ views on the role of
antidepressants in the management of their IBD are unknown. Thus, this study aimed to explore patients’
experiences and opinions regarding the effect of antidepressants on IBD course before possibly undertaking future
treatment trials with antidepressants.
Methods: Semi-structured in-depth interviews with open-ended questions were conducted with a randomly
selected sample of IBD patients recruited at the Australian public hospital IBD clinic and currently receiving
antidepressants. A qualitative content analysis was undertaken to summarise patients’ responses. A Visual Analogue
Scale was used to provide a quantitative assessment of patients’ experiences with antidepressants.
Results: Overall, 15 IBD sufferers currently on antidepressants (nine females, six males) were interviewed. All 15
reported a positive response to antidepressants reporting they improved their quality of life, with minimal side-
effects. Five patients (33.3%) felt the antidepressant had specifically improved their IBD course. Three patients noted
how they believed the reduction in feelings of stress mediated the positive influence of the antidepressant on IBD
course. Ten patients (66.7%) felt the antidepressants had not specifically influenced their IBD. Nine patients (60.0%)
had a generally positive attitude towards antidepressants, four patients (26.7%) were ambivalent, and two patients
(13.3%) held a negative view towards antidepressants. Twelve patients (80.0%) stated that they would be willing to
participate in clinical trials.
Conclusions: Antidepressants seem to be well tolerated by IBD patients. One third of patients reported an
observable improvement of their IBD under the influence of this treatment. The positive attitude towards
antidepressants in these participants may make the conduct of clinical trials to further assess for any specific role on
IBD course feasible. However, due to a small sample size, a qualitative nature of this study and in light of the results
of studies on other populations indicating reluctance to taking antidepressants at least in some patients, these
results should be interpreted with caution until confirmed in quantitative studies.
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Inflammatory bowel disease (IBD) is a group of chronic,
relapsing inflammatory disorders of the gut. The aetiology
of IBD is unknown, with genetic, immune and environ-
mental factors considered as important contributors to its
occurrence. Psychological status has been found to influ-
ence the timing of disease relapse [1,2]. Studies show a
30% rate of depression during remission [1], with 80% and
55% of patients reporting anxiety and depression, respect-
ively, during relapse [3]. While studies into psychological
therapies [4] have recently been conducted, antidepres-
sants have not been widely studied in the context of IBD.
However, studies with healthy volunteers have demon-
strated that antidepressants can improve immunoregula-
tory activity [5] and thus there is a potential for
antidepressants to not only help with psychological diffi-
culties but also positively impact the disease course.
Two systematic reviews analysing human and animal
studies have been conducted exploring the role of anti-
depressants in IBD, [6,7]. In humans, it was observed
that although antidepressants seem to improve both
mental and somatic status of IBD patients, the low qual-
ity of available research provides significant barriers to
making a definitive statement on their efficacy or lack
thereof [7]. Animal models however, found a positive
impact of antidepressants (i.e. desipramine and fluoxet-
ine) on inflammation in models of IBD [6]. When doc-
tors’ perspectives on antidepressants in IBD were
examined, it was reported that gastroenterologists com-
monly treat IBD patients with antidepressants for pain,
anxiety and/or depression, and insomnia [8]. Gastroen-
terologists reported that antidepressants were successful
in reducing pain, gut irritability, and urgency of
defecation. In the most recent retrospective case-note
audit, of 287 patients, 83 (28.9%) were found to have
used an antidepressant at some time in their life [9].
However, the design of the study does not allow one to
make a firm statement on whether antidepressants
improved IBD course. The most recent study in this area
[10] examining the disease course a year before and a
year after the commencement of antidepressants showed
that patients reported fewer relapses and steroid treat-
ment in the year after starting an antidepressant than in
the year before, which was not observed in the control
group. Whilst this report of decreased symptoms may
simply reflect the report of fewer functional gastrointes-
tinal symptoms when patients are in better psychological
health [11,12], it may also indicate an inflammation-
specific benefit from antidepressants. It is thus now clear
that randomised controlled trials are justified and
needed to provide the definitive answer on the efficacy
of antidepressants in IBD.
However, prior to embarking on a clinical trial in this
field we felt it prudent to explore patient views andexperiences with antidepressants and thus we selected a
group of antidepressant users. This is especially import-
ant as antidepressants are known to cause noticeable
side-effects [13]. This study therefore aims to explore
patients’ experiences and opinions regarding the effect
of antidepressants on IBD course as well as attitudes to-
wards future trials with antidepressants.
Methods
Setting
South Australia is the fourth largest of Australia's six
states and two territories, with >1.6 million inhabitants.
The Royal Adelaide Hospital (RAH) is the largest public
tertiary teaching hospital in South Australia (SA). At the
time of the study, the RAH IBD Service served ~550
IBD patients offering access to IBD nurses and psycholo-
gists with an interest in IBD.
Design and participants
A clinical case-note audit was performed reviewing over
300 of the available IBD patient files as described else-
where [9]. Inclusion criteria for invitation to participate
in this extension of the study were:
1) a diagnosis of IBD (Crohn’s disease (CD) or
ulcerative colitis (UC)) by a specialist
gastroenterologist
2) listed on the RAH IBD Service database
3) contact with RAH IBD Service within the preceding
6 months and
4) currently taking antidepressants.
Semi-structured in-depth interviews with open-ended
questions were conducted.
Procedure
Of 51 individuals who met the inclusion criteria, a ran-
dom sample of 15 was selected and invited for inter-
views. The interviews took place between January and
March 2011. The sample size was based on previous lit-
erature showing that data saturation is typically reached
with groups of 10–15 individuals [14]. In this case, data
saturation was reached after the 12th participant was
interviewed, however, the researchers decided to con-
duct the remaining three interviews as they had already
been booked. Interviews were performed face-to-face.
They were digitally recorded and transcribed verbatim.
Transcripts were then checked for accuracy.
Measurement
A protocol for semi-structured interviews was designed
by AM-W in collaboration with the remaining authors.
Questions were open-ended and pertained to: the history
of IBD and its course, reasons for taking antidepressants
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ment, etc.), acceptance of this treatment, patients’ obser-
vations in relation to side-effects and impact on IBD (e.g.
impact on pain, frequency of bowel movement), observed
impact on quality of life (QoL), attitudes towards antide-
pressants, and attitudes towards future trials with the
use of antidepressants. A Visual Analogue Scale (VAS)
designed for the purpose of this study was also used as
part of the interview (see Additional file 1: Appendix 1)
and the data collected as part of it are presented in
Table 1 and 2.
Analysis
A qualitative content analysis [14] was conducted by BS
in collaboration with the remaining authors. Firstly, the
transcripts were read twice to increase familiarity with
the data. Interviewer and respondent dialogue was then
transferred into Microsoft Excel (no qualitative
methods-specific software was used as Microsoft Excel
seemed adequate for the purpose of this analysis), with
each question given a separate worksheet, and each un-
interrupted segment of dialogue of the interviewer and
respondent given a separate cell within the worksheet
for a given question. Each segment of dialogue from a
respondent was sequentially and systematically coded
according to the explicit and implicit response to the
given question. Responses were coded in the context of
the question, any subsequent prompts or probes used by
the interviewer, and the preceding and following seg-
ments of dialogue from the interviewee in response to
that question. New codes were created when the implicit
or explicit content of a given segment of dialogue did
not correspond with a previously developed code. Any
interrelated questions and their respective codes were
allocated to groups based on the similar focus of given
sets of questions. Following the coding of all questions
in a given group, the codes and general trends were
assessed across questions. Any new emerging codes or
inconsistencies observed were used to revise the content
analysis. Codes were then summarised and quantified
where appropriate and the analysis was written up using
descriptive statistics and supporting quotes where neces-
sary. Codes were checked by two independent reviewers
(BS and AMW), the presence/absence of divergent pa-
tient views was discussed and a high inter-raterTable 1 Visual Analogue Scale scores for the acceptability of
Analogue Scale in 2011
How many side effects do you feel from this drug? (scale 0–100, from n
How much do side-effects from this drug bother you? (scale 0–100, fro
How much do you like this drug? (scale 0–100, from not at all to a lot)
Does this drug make you feel more “normal”? (scale 0–100, from definreliability was achieved. Summary statistics were used to
summarise the data from the VAS scale.
Ethical considerations
This study was approved by the Royal Adelaide Hospital
and University of South Australia Research Ethics Com-
mittees. Selected patients were invited to the study by
their treating doctors and contacted by BS only after
they expressed their interest to the treating doctor. Each
participant gave written informed consent prior to their
interview and patient anonymity was preserved. Patients
were given adequate time to familiarise themselves with
the information about the study and discuss participa-
tion with family and/or friends. They were informed
they could withdraw from the study anytime without
any consequence for their future treatment at the clinic.
The study was conducted in compliance with the Dec-
laration of Helsinki.
Results
Patient characteristics
All 15 IBD subjects invited to participate actually partici-
pated in the interview study. On average interviews
lasted 30 min. Of these, nine (60%) were female. The
mean age was 45.8 (SD= 17.11) years, with the mini-
mum of 20 years and the maximum of 81 years. Twelve
patients (80.0%) had CD, two patients had UC (13.3%),
and one patient had colitis of undetermined aetiology.
The time since diagnosis ranged from three to 30.5 years
(M= 16.8, SD= 8.9). The number of current symptoms
reported per patient ranged from one to seven (M= 3.5,
SD= 2.0). The most commonly reported symptoms were
pain (86.7%), diarrhoea (66.7%), nausea (33.3%), fatigue
26.7%, bloating (26.7%), and difficulties tolerating medi-
cations (20.0%).
Antidepressant treatment
Reasons for taking antidepressant treatment
Patients reported between one and three (M= 1.63, SD=
0.81) reasons for taking an antidepressant. The most
commonly stated reasons were depression or depressed
mood, reported by 10 patients (66.7%), and anxiety or
anxious mood, reported by seven patients (46.7%). Other
reported reasons included sleeping problems, stress,antidepressants (n = 15) collected as part of the Visual
Mean (SD) Qualitative score
one – a lot) 12.86 (22.05) Few
m not at all to a lot) 5.2 (7.4) Very little
60.8 (31.28) Like it
itely no to definitely yes) 78.57 (24.70) Yes
Table 2 Advantages and disadvantages of the treatment with antidepressants for each patient collected as part of the
Visual Analogue Scale in 2011
Patient No. Advantages Disadvantages
1 No side effects, efficacy Nothing
2 Makes me feel happier, stops me getting angry quickly Nothing
3 Feeling less anxious and depressed especially towards
the evening
None
4 Able to sleep better at night Can make you feel groggy in morning if I haven't slept it off
5 When they do work I feel a lot more confident and secure If it doesn't work sometimes I break down or become more aggressive
6 Prozac makes me feel that I can cope with day to day activities Not being able to stop taking Prozac
7 Helps to cope with my illness Sleep too much
8 Couldn't adequately answer as long time since starting
a treatment
Couldn't adequately answer as long time since starting a treatment
9 Stops me running to toilet Heart burn
10 Less feelings of hopelessness Stomach pain
11 Relaxation and improvement in sleep Having to take them
12 I am able to live a better qol with a more positive attitude
and energy to partake in day-to-day life activities
Possibility of becoming dependent on it later on in life
13 You do not notice it Nothing
14 Don't experience the deep depression anymore Weight gain, don't experience the high enjoyment anymore
15 I don't know I am having the drug Nothing
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compulsive disorder.Antidepressant treatment history
For the majority of patients (13, 86.7%) their current or
recent treatment with antidepressants was the first time
they had received the treatment. The duration of anti-
depressant treatment ranged from four and a half
months to 13 years, with an average of 5.6 years (SD=
4.8). The most commonly prescribed medications were
Amitriptyline and Sertraline, with three patients (20.0%)
each, followed by Paroxetine and Escitalopram with two
patients (13.3%) each, and Duloxetine, Nortriptyline,
Fluoxetine, Citalopram, and Mirtazapine being used by
one patient each.
The majority of patients (10, 66.7%) reported experien-
cing no side effects from antidepressant therapy. Five
patients (33.3%) reported experiencing between one and
three distinct side effects (M= 2.3, SD= 0.6), with two
patients reporting dry mouth, and one patient each
reporting diarrhoea, abdominal pain, headaches, weight
gain, heart burn, emotional numbness, and anhedonia.
One patient reported a cessation of the side effects of
antidepressant treatment after a change in the type of
antidepressant he was using from Mirtazapine to Sertra-
line. Three patients (20.0%) discussed the difficulty in
dissociating symptoms that may be side effects of anti-
depressant treatment from the side effects of other med-
ications they were using, or IBD symptoms.“It can be difficult to tell when you’ve got something like
Crohn’s because anything could be an effect of the- I’m
on three different medications. Four if you count the
Loperamide. So anything could be a side effect of one of
those or it could be the Crohn’s itself.” (Patient 14)
The efficacy of antidepressant treatment
When asked if treatment with antidepressants had
helped them or improved their QoL, all fifteen patients
indicated that it had. The areas of improvement cited
were primarily psychological, but some patients indi-
cated social as well as biological areas of improvement
in their lives. Three patients expressed some uncertainty
in dissociating the causes for their improvements from
the three areas of antidepressant treatment, other psy-
chotropic medications, and psychological treatment. The
most common area of improvement was a reduction in
anxiety, anxious mood, or stress, and an increase in the
ability to relax, reported by ten patients (66.7%).
“. . .it definitely curbs. . . you know the anxiety sort of
panic attack type stuff. . . Look I’d have to say it’s
working cause I don’t notice it anymore so. . .” (Patient 5)
Eight patients (53.3%) reported a reduction in depres-
sion or depressed mood.
“I mean I tend to get fairly depressed in the evenings.
More than anything, you know, it does tend to help
that. . .” (Patient 6)
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had reduced their irritability or anger.
“Definitely stops me from being bad-tempered or
moody.” (Patient 2)
Four patients (26.7%) described subsequent improve-
ments in: their capacity to do more housework, paid
work, or education; their ability to engage with partners,
family, or friends; and their capability to participate in
social or recreational activities.
“. . .I think my relationship with my husband has
improved a lot because I. . . when I’m at my lowest,
I’m pushing him away. Whereas, now that I’m
actually. . . feeling closer towards him and, you know,
feeling like I want him to be part of my life now more
than I did at the beginning of the year when I wanted
to push him away so. . . I think it improves
relationships. I mean I guess that’s just because of my
mental attitude has changed so much.” (Patient 1)
Similarly, two patients reported increased energy and
motivation to engage in these activities.
“So I definitely feel more energy. I’m positive now. I
don’t look at everything as a negative anymore. If I
have a flare-up, I might get down about it. But then,
you know, move on straight away. I’m still doing things
like working, making an effort to go to my shifts even
when I’m unwell. I’m just pushing myself that little bit
extra. So it’s definitely given me more of a quality of
life.” (Patient 4)
Three patients (20.0%) felt that the antidepressant treat-
ment had improved their cognitive processes by giving
them increased control over their thoughts, improving the
clarity of their thoughts, and reducing irrational thought
processes. Three other patients described improvements
in their sleeping patterns, although this may have been
associated with coinciding improvements in other areas of
functioning such as improvements in the ability to relax
and reductions in the experience of anxiety and pain.
“Yep. I find I relax a lot better at night. I get a better
night’s sleep. There’s obviously still nights where I toss
and turn and I wake up and the ileostomy could be
playing up, so that’s a big factor in the sleep problem
too. But otherwise, nah I feel like I’ve got some sort of
routine within my body so I do get at least seven hours
of sleep at night instead of the two.” (Patient 12)
Finally, three patients also discussed how the anti-
depressant treatment had helped them cope with thestressors in their life, particularly those posed by their
disease.
“Yes. . . It’s helping me cope with what’s wrong with
me. It’s hard to- to deal with sometimes. . .” (Patient 9)
Improvements in disease function
Three patients (20.0%) raised, unprompted, the feeling
that the antidepressant treatment had ameliorated phys-
ical symptomatology associated with their disease, in-
cluding reducing the frequency of symptoms or flare-ups
of disease.
“And I honestly believe it helps me with this disease.”
(Patient 2)
When asked specifically whether the antidepressant
had influenced their IBD in terms of pain, frequency of
bowel movement, or frequency of relapses, 10 patients
(66.7%) felt that the antidepressant treatment had not
influenced their disease course. Two patients (13.3%)
described again how it was difficult to dissociate the
effects of the antidepressant on the disease course from
other possible causal mechanisms. Of the five patients
who felt the antidepressant had influenced their disease
course, three discussed how the reduction in feelings of
stress mediated the influence of the antidepressant on
improving the disease course.
“. . . when the OCD was full-blown, naturally that was
incredibly stressful and I was very sick at the time. So
I suppose the main effect of it is just to calm me down
and take away that aspect.” (Patient 14)
Of the five patients (33.3%) who felt the antidepressant
had improved their disease course, three patients
described a reduction in pain, two described reductions
in the frequency of bowel movement, one described a
reduction in nausea, and one patient also felt that the
frequency of relapses of disease had reduced.
Attitudes towards antidepressants
Patients’ responses on the VAS summarising their ac-
ceptance of antidepressants are presented in Table 1.
Patients reported a reasonable level of acceptance of the
treatment with antidepressants. Patients’ perceived
advantages and disadvantages of the treatment are listed
in Table 2.
Despite every patient indicating earlier that antidepres-
sants had increased their quality of life, patients’ views
or attitudes towards antidepressants in general were not
as unilaterally positive. Nine patients (60.0%) had a gen-
erally positive attitude, four patients (26.7%) were am-
bivalent, and two patients (13.3%) held a negative view
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the potential benefits need to be contrasted against the
costs of antidepressant treatment in the individual con-
text of each person. Potential benefits listed included an
improvement in mood and functioning, while the poten-
tial costs included side effects and the concern of be-
coming dependent. Some patients also raised the
concern that while antidepressants may superficially fix
a problem, they did not solve the underlying cause.
“Obviously because they can be addictive and, from
what I hear, you know you get on them and then you
think you’re okay so you stop them and then you go
downhill again and you gotta basically stay on them
to flatline. But, yes I didn’t want them. I don’t wanna
be walking around zombified or making some pill
make me feel happy when it shouldn’t be a pill. It
should be just because life’s good. . . It just depends on
the person I suppose.” (Patient 12)
One patient felt that there may be a perception that
antidepressants are a ‘magic pill’ which may be perpetu-
ated by doctors and could need dispelling.
“Yeah. Cause it’s like “Okay take this pill and-” Not
that they say that but. . . you know, it’s more or less
“Alright take this medication and things are going to
get better” and stuff like that, so you have your hopes
up high and if you don’t have a GP that’s on it and
knows what they’re doing and what ones are best for
you. . . like I think you can get worse off than where
you first started. But I’m sure they are beneficial, I
mean I know people that have been on them. . . that
have had a lot of benefit out of them. . . I just wasn’t
one of those people I guess.” (Patient 3)
Despite the sizeable minority who expressed ambiva-
lent or negative attitudes regarding antidepressant use,
fourteen patients (93.3%) stated that they would recom-
mend antidepressants to other IBD patients. However, of
these, four patients (36.4%) expressed some reluctance
and placed certain provisos on this recommendation,
whereby antidepressant treatment would depend on the
individual’s circumstances.Potential clinical trials
Finally, patients were asked whether they would be will-
ing to potentially participate in a clinical trial if there
were evidence for antidepressants to play a role in the
management of IBD. Twelve patients (80.0%) stated that
they would while three would not. Six patients (40.0%)
stated that they would in order to help improve treat-
ment for other IBD patients. Four patients (26.7%) saidthey would be interested in order to improve their own
quality of life.
Of the factors which detracted from their willingness
to participate in a future trial, two patients felt that the
side-effects of antidepressants were not worth the poten-
tial benefit.
“. . .for some reason medication doesn’t sit well with
me. And like I’ve got to the point now where, as I said,
I’d rather just live with my disease than all the other
side effects that come from all the. . . medication.”
(Patient 3)
Two patients did not want to change their current
antidepressant medication due to their success with it.
“I might but as I say I’m so suited with the Zoloft I’m
sort of edgy about the idea of changing it.” (Patient 14)
One patient (6.7%) felt that because their antidepres-
sant use hadn’t affected their IBD in any way they would
not wish to participate, and one patient felt too unwell
to undertake the travel commitment necessary for par-
ticipation in a trial.
Discussion
This paper is the first to explore patients’ views on the
role of antidepressant drug therapy in IBD and one of
very few human clinical studies exploring the use of
antidepressants in IBD sufferers.
The paper documents that IBD patients are prescribed
antidepressants for mental health issues rather than
somatic symptoms which contrasts slightly with their
typical use in patients with functional gastrointestinal
disorders (FGIDs), and irritable bowel syndrome (IBS) in
particular, who are frequently offered antidepressants to
treat both somatic and psychological complains [15].
Due to the proposed aetiology of IBS symptoms which
includes psychological factors and also thanks to several
studies into the efficacy of antidepressants in FGIDs,
antidepressants have now become a part of the standard
treatment for IBS, offering significant benefits to patients
[16]. Previous work has shown that gastroenterologists
commonly use antidepressants in IBD patients for symp-
toms commonly encountered in IBS [8]. IBD and IBS
share symptomatology and some other characteristics
[17] and some researchers have argued they may, in fact,
be two different ends of the spectrum of the same condi-
tion; one with lesser symptoms and greater inflamma-
tion, the other with greater symptoms and minimal
inflammation [18,19].
Moreover there is now a growing appreciation that
IBS can occur in healed IBD [11,12] and that without
endoscopic examination, the precise cause of symptoms
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ticular point in time. Yet, there are very few studies that
have critically examined the role of antidepressants in
IBD. In support of the concept that antidepressant ther-
apy may be of real efficacy in IBD, and in fact offer a
more specific benefit here than in IBS, several studies
have now reported anti-inflammatory properties in cer-
tain antidepressants [5,20,21]. Moreover, in animal mod-
els antidepressant therapy has now been documented to
ameliorate visible GI inflammation [22,23]. Thus, antide-
pressants may potentially offer additional benefit to IBD
patients with active inflammation, assisting with mental
health but also directly reducing inflammation. For this
reason clinical trials in this area are needed and are
likely to be conducted in the future.
However, since antidepressants have been shown to
have a high occurrence of side-effects [24,25], many
leading to medication changes or intolerance [26], it
seems prudent to examine patients’ perspectives on the
use of antidepressants in IBD and collect their observa-
tions prior to planning future trials, to better inform
their design. This paper has shown that patients do not
report many side-effects and if they experience any,
these do not seem to significantly impact them. How-
ever, one of the weaknesses of the current study is that
we have, as yet, only sought the opinions of patients
who have chosen to continue to take antidepressants
(leading perhaps to an overly optimistic outlook). In fu-
ture, it would also be informative to seek to interview
those who either were not offered antidepressants, and
others who may have been prescribed these agents, yet
did not continue therapy. Patients also report medica-
tion side effects from standard IBD treatments and it is
sometimes difficult to judge which side-effect comes
from which medication. Clearly, this is a highly medi-
cated group of patients and thus the risk of causing
more side-effects must be considered when planning fu-
ture studies. Yet, this group of interviewed patients lists
more advantages than disadvantages of treatment with
antidepressants.
Even though patients observe benefits to their mental
health and overall quality of life, only five of them com-
mented on the drug impacting on their disease course. In
the remaining patients, the medication was thought to
offer psychological benefit, also with respect to motivation
and cognitive functions. In terms of physical symptoms,
antidepressants were noted to improve sleep. This obser-
vation was previously made by interviewed gastroenterol-
ogists [8] who emphasised that their patients while on
antidepressants had not reported needing to visit a toilet
during night with better controlled bowel functions –
which could be either due to better sleep or improved dis-
ease control or both – emphasizing the difficulty in
present data in determining whether antidepressantsimprove only symptoms, or also disease activity. The five
patients reporting reduction in IBD symptoms, and im-
provement in pain, fewer bowel movements and less fre-
quent relapses of IBD in particular, interestingly
conceptualised that this was due to a reduction in per-
ceived stress. And this was thought to mediate the influ-
ence of antidepressants on disease course. This
observation will need to be however confirmed in clinical
trials as the present design does not allow for testing this
hypothesis.
With respect to patients’ attitudes towards antidepres-
sants, these were largely positive. However, patients dis-
cussed their worries that the treatment could be only
superficial, offering relief while ongoing and they clearly
feared dependence. There is an ongoing debate on
whether antidepressants may in fact cause dependence
[27], and in any case, presenting problems when tapering
off [28], with significant numbers of patients no longer
needing an antidepressant for their mental health prob-
lem yet suffering unbearable withdrawal effects while
discontinuing and thus remaining on treatment [29].
Nevertheless, patients participating in this study
reported antidepressants to be a medication worth
recommending to fellow IBD sufferers as long as the de-
cision of their use was taken after consideration. Al-
though studies exploring attitudes to antidepressant use
in larger samples or in samples recruited in primary care
(and thus with possibly better controlled IBD) are not
available, studies conducted in the general population in
primary care showed a less receptive attitude to antide-
pressants. For example, a survey of 1,054 primary care
users showed that over 20% of them did not disclose de-
pressive symptoms to their doctors out of the fear anti-
depressants will be prescribed [30]. Other studies have
reported non-adherence to treatment with antidepres-
sants due to patient beliefs or misconceptions about this
type of medication [31,32]. In light of these findings, the
positive attitudes to antidepressants identified in the
present study should be interpreted with caution and
confirmed by larger quantitative studies with more rep-
resentative IBD samples.
The most positive outcome in this study was patients’
positive attitude towards clinical trials with the use of
antidepressant. Overall, 80% of this study’s participants
reported willingness to participate in such trials with the
hope such studies could help other people but also their
own quality of life. Those few rejecting the idea of par-
ticipating in such a study reported lack of faith in anti-
depressants really being effective in IBD or claiming the
benefits were not worth the harm caused by the side-
effects. However, these patients agreed to participate in
the present research study and thus there is a potential
that they are generally more willing to participate in
studies than an average IBD patient and thus this result
Mikocka-Walus et al. BMC Gastroenterology 2012, 12:93 Page 8 of 9
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should be conducted to explore the attitudes of general
IBD population towards antidepressants.
Conclusion
Antidepressants seem to be well tolerated by IBD
patients. One third of patients perceived an improve-
ment of their IBD under the influence of this treatment.
The positive attitude towards antidepressants in these
participants may make the conduct of clinical trials to
further assess for any specific role on IBD course feas-
ible. However, due to a small sample size, a qualitative
nature of this study and in light of the results of studies
on other populations indicating reluctance to taking
antidepressants at least in some patients, these results
should be interpreted with caution until confirmed in
quantitative studies.Additional files
Additional file 1: APPENDIX. Visual analogue scale regarding the use
of antidepressants.
Competing interests
Authors declare that they have no competing interests in relation to this
study.
Acknowledgements
This study was funded from the University of South Australia, School of
Nursing and Midwifery Research Grant Scheme 2010.
Author details
1School of Nursing and Midwifery, Sansom Institute for Health Research,
University of South Australia, Adelaide, Australia. 2School of Psychology,
University of Adelaide, Adelaide, Australia. 3IBD Service, Department of
Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide,
Australia. 4School of Medicine, University of Adelaide, Adelaide, SA, Australia.
Authors’ contributions
AAMW contributed to the design of the study, data analysis and
interpretation, prepared the first and approved the final draft. ALG
contributed to the design of the study, data interpretation, provided
feedback on drafts and approved the final draft. BJS contributed to the
design of the study, data collection, analysis and interpretation, provided
feedback on drafts and approved the final draft. JMA contributed to the
design of the study, data interpretation, provided feedback on drafts and
approved the final draft. All authors read and approved the final manuscript.
Authors’ information
AAMW is a research psychologist working in the area of Psycho-
gastroenterology with a particular interest in testing psychosocial
interventions to manage IBD and other chronic gastrointestinal conditions.
She is the author of two systematic reviews and other research papers on
the role of antidepressants in IBD. ALG is a pharmacologist with an interest
in substance use and mental health and has an expertise in pharmacology
of antidepressants. BJS is a psychology doctoral student with an interest in
psychotherapeutic and psychiatric interventions to manage chronic
gastrointestinal and hepatologic conditions. JMA is an Associate Professor of
Medicine and a Senior Clinician in Gastroenterology, Head of IBD Service
with an interest in biopsychosocial therapies to co-manage IBD and other
gastrointestinal conditions.
Received: 13 October 2011 Accepted: 20 July 2012
Published: 20 July 2012References
1. Mittermaier C, Dejaco C, Waldhoer T, Oefferlbauer-Ernst A, Miehsler W, Beier
M, Tillinger W, Gangl A, Moser G: Impact of Depressive Mood on Relapse
in Patients With Inflammatory Bowel Disease: A Prospective 18-Month
Follow-Up Study. Psychosom Med 2004, 66(1):79–84.
2. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M: A
prospective population-based study of triggers of symptomatic flares in
IBD. Am J Gastroenterol 2010, 105(9):1994–2002.
3. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G: Inflammatory bowel
disease: a study of the association between anxiety and depression,
physical morbidity, and nutritional status. Scan J Gastroenterol 1997, 32
(10):1013–1021.
4. Timmer A, Preiss JC, Motschall E, Rucker G, Jantschek G, Moser G:
Psychological interventions for treatment of inflammatory bowel
disease. Cochrane Database Syst Rev 2011, 16(2):CD006913.
5. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, Marmurowska-
Michalowska H, Kandefer-Szerszen M: In vitro immunoregulatory effects of
antidepressants in healthy volunteers. Pol J Pharmacol 2003, 55(3):353–362.
6. Mikocka-Walus A, Clarke D, Gibson P: Can antidepressants influence the
course of inflammatory bowel disease (IBD)? A current state of research.
European Gastroeneterology and Hepatology Review 2009, 5(1):48–53.
7. Mikocka-Walus A, Turnbull DA, Moulding NT, Wilson IG, Andrews JM,
Holtmann GJ: Antidepressants and inflammatory bowel disease: a
systematic review. Clin Pract Epidemol Ment Health 2006, 2:24.
8. Mikocka-Walus A, Turnbull DA, Moulding NT, Wilson IG, Andrews JM,
Holtmann GJ: "It doesn't do any harm, but patients feel better": a
qualitative exploratory study on gastroenterologists' perspectives on the
role of antidepressants in inflammatory bowel disease. BMC Gastroenterol
2007, 7:38.
9. Mikocka-Walus A, Gordon A, Stewart B, Andrews JM: The role of
antidepressants in the management of inflammatory bowel disease
(IBD): A short report on a clinical case-note audit. Journal of
Psychosomatic Research 2011, 72(2):165–167.
10. Goodhand JR, Greig FIS, Koodun Y, McDermott A, Wahed M, Langmead L,
Rampton DS: Do Antidepressants Influence Disease Course in IBD? A
Retrospective Case-Matched Observational Study. Inflammatory Bowel
Diseases 2011, in press.
11. Bryant RV, van Langenberg DR, Holtmann GJ, Andrews JM: Functional
Gastrointestinal Disorders in Inflammatory Bowel Disease: Impact on
Quality of Life and Psychological Status. J Gastroenterol Hepatol 2011, 26
(5):916–923.
12. Mikocka-Walus A, Turnbull DA, Andrews JM, Moulding NT, Holtmann GJ:
The effect of functional gastrointestinal disorders on psychological
comorbidity and quality of life in patients with inflammatory bowel
disease. Aliment Pharmacol Ther 2008, 28(4):475–483.
13. Rang HP, Dale MM, Ritter JM: Rang & Dale's Pharmacology. 6 ednth edition.
London: Churchil Livingstone; 2007.
14. Creswell JW: Research design: Qualitative, quantitative, and mixed methods
approaches. Thousand Oaks: Sage; 2003.
15. Grover M, Drossman DA: Psychotropic agents in functional
gastrointestinal disorders. Curr Opin Pharmacol 2008, 8(6):715–723.
16. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P: Efficacy of
antidepressants and psychological therapies in irritable bowel syndrome:
systematic review and meta-analysis. Gut 2009, 58(3):367–378.
17. Spiller RC: Overlap between irritable bowel syndrome and inflammatory
bowel disease. Dig Dis 2009, 27(Suppl 1):48–54.
18. Mearin F, Perello A, Balboa A: Irritable bowel syndrome and inflammatory
bowel disease: Is there a connection? Gastroenterol Hepatol 2009, 32
(5):364–372.
19. Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade
inflammatory bowel disease? Gastroenterol Clin North Am 2005, 34(2):6–7.
20. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M,
Wiktorowicz K: Interleukin-6 serum levels in depressed patients before
and after treatment with fluoxetine. Ann N Y Acad Sci 1995, 762:474–476.
21. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M: Anti-
Inflammatory effects of antidepressants through suppression of the
interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol
2001, 21(2):199–206.
22. Ghia JE, Blennerhassett P, Collins SM: Impaired parasympathetic function
increases susceptibility to inflammatory bowel disease in a mouse
model of depression. J Clin Invest 2008, 118(6):2209–2218.
Mikocka-Walus et al. BMC Gastroenterology 2012, 12:93 Page 9 of 9
http://www.biomedcentral.com/1471-230X/12/9323. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM:
Reactivation of inflammatory bowel disease in a mouse model of
depression. Gastroenterology 2009, 136(7):2280–2288. e2281-2284.
24. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE,
Lohr KN: Comparative risk for harms of second-generation
antidepressants: a systematic review and meta-analysis. Drug Saf 2008,
31(10):851–865.
25. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H,
Churchill R, Furukawa TA: Safety reporting and adverse-event profile of
mirtazapine described in randomized controlled trials in comparison
with other classes of antidepressants in the acute-phase treatment of
adults with depression: systematic review and meta-analysis. CNS Drugs
2010, 24(1):35–53.
26. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study
[http://www.nimh.nih.gov/trials/practical/stard/index.shtml]
27. Haddad PM: Do antidepressants cause dependence? Epidemiol Psichiatr
Soc 2005, 14(2):58–62.
28. Shelton RC: The nature of the discontinuation syndrome associated with
antidepressant drugs. J Clin Psychiatry 2006, 67(Suppl 4):3–7.
29. Glenmullen J: Coming Off Antidepressants. London: Robinson Publishing;
2006.
30. Bell RA, Franks P, Duberstein PR, Epstein RM, Feldman MD, Fernandez-Y-
Garcia E, Kravitz RL: Suffering in silence: reasons for not disclosing
depression in primary care. Annals of family medicine 2011, 9(5):439–446.
31. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J:
Beliefs about antidepressant medications in primary care patients:
relationship to self-reported adherence. Medical care 2005,
43(12):1203–1207.
32. Russell J, Kazantzis N: Medication beliefs and adherence to
antidepressants in primary care. N Z Med J 2008, 121(1286):14–20.
doi:10.1186/1471-230X-12-93
Cite this article as: Mikocka-Walus et al.: A magic pill? A qualitative
analysis of patients’ views on the role of antidepressant therapy in
inflammatory bowel disease (IBD). BMC Gastroenterology 2012 12:93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
